Deutsche Bank downgraded Oxford BioMedica from 'buy' to 'hold' and cut its target price by 26% to 595p due to slower revenue growth and delays in its programmes. The bank noted operational issues at the company's Durham site and weaker visibility ahead of its capital markets day, increasing uncertainty about future growth. Revenue estimates for 2026 and 2027 were lowered by about 20%, with a larger impact on earnings and EBITDA. The downgrade reflects concerns over execution risks despite a more attractive valuation after the share price decline.
Blue Owl is highlighted as a deep value investment opportunity with improving fundamentals and a strong recovery from previous market pessimism. Its real assets segment has driven 44% revenue growth over the past year, with expectations for continued...
In July 2026, three major Bitcoin mining firms—CleanSpark, BitFuFu, and Canaan—each reported lower Bitcoin production compared to June, marking a second consecutive monthly decline. This drop occurred despite Bitcoin's price recovering from a sharp J...
OpenAI has introduced a new ChatGPT for Teens platform designed specifically for users aged 13 to 17, featuring enhanced safety measures to protect young users. The platform includes study aids developed with Stanford University, quizzes, responsible...
Southern California Gas Co. (SoCalGas) delivered over $10 million in no-cost energy efficiency upgrades to schools, local governments, and public facilities in 2025 through its Public Direct Install Program (PDIP). These upgrades, including high-effi...
US stock futures are down, led by a 1% drop in the Nasdaq-100, due to escalating tensions in the Middle East. President Trump's threats against Oman and Iran have driven oil prices up to their highest in two weeks, with Brent crude at $91 a barrel. R...
